TYK MEDICINES-B Shares Surge Over 5% Following H-Share Reform Completion and New Drug Application Milestone

Stock News03-06 12:01

TYK MEDICINES-B (02410) rose more than 5%, with a gain of 4.92% at the time of writing to HK$11.34, generating a turnover of HK$27.5877 million. On March 4, the company announced that the conversion of 4.608 million non-listed shares into H-shares was completed on March 4, 2026. These converted H-shares are scheduled to commence trading on the Stock Exchange of Hong Kong at 9:00 a.m. on March 5, 2026. Recently, TYK MEDICINES-B announced that the new drug application for its self-developed TY-9591 mesylate tablets, targeting brain metastases in non-small cell lung cancer, has been formally accepted by the Center for Drug Evaluation of China's National Medical Products Administration. This marks the first next-generation EGFR-TKI inhibitor specifically for lung cancer brain metastases. The NDA submission is based on results from a key multicenter, randomized, open-label, active-controlled registrational clinical study conducted in China. The study's findings are expected to be presented at an upcoming international academic conference or published in a scientific journal.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment